Monday, 9 Feb 2026
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • House
  • ScienceAlert
  • VIDEO
  • White
  • man
  • Trumps
  • Watch
  • Season
  • Years
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Economy > Here’s What to Expect From Johnson & Johnson’s Next Earnings Report
Economy

Here’s What to Expect From Johnson & Johnson’s Next Earnings Report

Last updated: June 28, 2025 4:00 am
Share
Here’s What to Expect From Johnson & Johnson’s Next Earnings Report
SHARE

Johnson & Johnson (JNJ) is a leading healthcare company headquartered in New Brunswick, New Jersey. The company is known for its research and development, manufacturing, and sale of various healthcare products worldwide. With a market capitalization of $366.4 billion, Johnson & Johnson operates through its Innovative Medicine and MedTech segments.

The company is gearing up to announce its second-quarter results on Wednesday, July 16. Analysts are projecting a non-GAAP earnings of $2.65 per share, a 6% decrease from the previous year. Despite the anticipated decline, Johnson & Johnson has consistently exceeded analysts’ expectations in recent quarters. For the full fiscal year 2025, earnings are expected to reach $10.60 per share, representing a 6.2% increase from the previous year. In fiscal 2026, earnings are projected to rise by 3.6% year-over-year to $10.98 per share.

Over the past 52 weeks, JNJ stock has shown a 3.5% growth, outperforming the Health Care Select Sector SPDR Fund’s 8.1% decline but falling short of the S&P 500 Index’s 12.1% increase during the same period. Despite delivering better-than-expected financial results in the first quarter, Johnson & Johnson’s stock experienced a slight dip initially. However, the company’s solid growth in US sales led to a 2.4% year-over-year increase in overall revenue to $21.9 billion. Additionally, adjusted earnings per share rose by 2.2% to $2.77, exceeding consensus estimates.

Analysts have a cautiously optimistic outlook on JNJ, with a “Moderate Buy” rating overall. Of the 23 analysts covering the stock, nine rate it as a “Strong Buy,” two as a “Moderate Buy,” and 12 as a “Hold.” The mean price target of $169.14 suggests an 11.3% upside potential from the current price levels.

See also  Evercore Reiterates Outperform on Meta Platforms (META) Ahead of Earnings

In conclusion, Johnson & Johnson continues to demonstrate resilience and growth in the healthcare industry. Investors are eagerly awaiting the company’s upcoming earnings report to gain further insights into its financial performance and future outlook. This article was originally published on Barchart.com and is intended for informational purposes only.

TAGGED:EarningsExpectHeresJohnsonJohnsonsreport
Share This Article
Twitter Email Copy Link Print
Previous Article Creating Bird Flu Vaccines for Humans at a Biosecure Laboratory Creating Bird Flu Vaccines for Humans at a Biosecure Laboratory
Next Article Summer 2025 Hot Shots … June Gloom?! More Like June Bloom! Summer 2025 Hot Shots … June Gloom?! More Like June Bloom!
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

The Best Hotels in Kyoto, From Private Retreats to Modern Ryokan

As you approach Maana Kiyomizu, you'll meander down a charming narrow alley that most taxis…

April 15, 2025

Types, Benefits, Use Cases, Future Trends, & More

Integrating Artificial Intelligence (AI) into Enterprise Resource Planning (ERP) systems is a transformative step that…

May 16, 2025

The Naked Gun Review: Charged With Man’s Laughter

The Naked Gun franchise has always been a beloved classic in the realm of comedy,…

July 30, 2025

Inside China’s lies

Talking about the Uyghurs wasn’t on my agenda. It all began with a casual reference—merely…

June 12, 2025

Oilers HC Kris Knoblauch makes his opinion clear about team’s belief in Stuart Skinner after humiliating 9-1 loss to Avalanche

The Edmonton Oilers suffered a devastating 9-1 loss to the Colorado Avalanche in their recent…

November 9, 2025

You Might Also Like

These are all the companies pledging matching funds to Trump accounts
Economy

These are all the companies pledging matching funds to Trump accounts

February 9, 2026
Gold price today, Monday, February 9: Gold opens above ,000
Economy

Gold price today, Monday, February 9: Gold opens above $5,000

February 9, 2026
Wedbush Lowers AppLovin (APP) PT to 5, Cites Valuation Reset, Industry Headwinds
Economy

Wedbush Lowers AppLovin (APP) PT to $465, Cites Valuation Reset, Industry Headwinds

February 9, 2026
Analysts Reiterate Buy Rating For Capital One Financial (COF) Despite Disappointing Earnings
Economy

Analysts Reiterate Buy Rating For Capital One Financial (COF) Despite Disappointing Earnings

February 9, 2026
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?